(19)
(11) EP 4 271 374 A1

(12)

(43) Date of publication:
08.11.2023 Bulletin 2023/45

(21) Application number: 21916206.2

(22) Date of filing: 16.12.2021
(51) International Patent Classification (IPC): 
A61K 31/404(2006.01)
C07D 401/04(2006.01)
C07D 209/08(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 401/04; C07D 405/04; C07D 409/04; C07D 471/04; C07D 405/12; C07D 307/20; C07D 403/04; C07D 231/56
(86) International application number:
PCT/US2021/063685
(87) International publication number:
WO 2022/146698 (07.07.2022 Gazette 2022/27)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 29.12.2020 US 202063131674 P

(71) Applicant: Revolution Medicines, Inc.
Redwood City, CA 94063 (US)

(72) Inventors:
  • BUCKL, Andreas
    Redwood City, California 94063 (US)
  • THOMPSON, Severin
    Redwood City, California 94063 (US)
  • GILL, Adrian L.
    Redwood City, California 94063 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)

   


(54) SOS1 INHIBITORS AND USES THEREOF